Jiangsu Cancer Institute & Hospital

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab and chemotherapy as a first treatment for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this mix shrinks tumors and how safe…

This study tests whether adding low-dose radiation and an immunotherapy drug (tislelizumab) to standard chemotherapy improves outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 114 participants will be randomly assigned to receive either …

This study tests whether giving a short course of focused radiation (SBRT) along with immunotherapy (iparomlimab and tuvonralimab) and chemotherapy before surgery can improve outcomes for people with early-stage non-small cell lung cancer. About 24 adults in China will receive th…

This study looks at tissue samples from 60 people newly diagnosed with nasopharyngeal cancer that has not spread. Researchers will analyze genetic markers to see if they can predict how well the cancer responds to treatment and how long patients live. The goal is to improve futur…